The lack of accurate in vitro assays for predicting in vivo toxicity of chemicals together with new legislations demanding replacement and reduction of animal testing has triggered the development of alternative methods. This study aimed at developing a transcriptomics-based in vitro prediction assay for in vivo genotoxicity. Transcriptomics changes induced in the human liver cell line HepG2 by 34 compounds after treatment for 12, 24, and 48 h were used for the selection of gene-sets that are capable of discriminating between in vivo genotoxins (GTX) and in vivo nongenotoxins (NGTX). By combining transcriptomics with publicly available results for these chemicals from standard in vitro genotoxicity studies, we developed several prediction models. These models were validated by using an additional set of 28 chemicals. The best prediction was achieved after stratification of chemicals according to results from the Ames bacterial gene mutation assay prior to transcriptomics evaluation after 24 h of treatment. A total of 33 genes were selected for discriminating GTX from NGTX for Ames-positive chemicals and 22 for Ames-negative chemicals. Overall, this method resulted in 89% accuracy and 91% specificity, thereby clearly outperforming the standard in vitro test battery. Transcription factor network analysis revealed HNF3a, HNF4a, HNF6, androgen receptor, and SP1 as main factors regulating the expression of classifiers for Ames-positive chemicals. Thus, the classical bacterial gene mutation assay in combination with in vitro transcriptomics in HepG2 is proposed as an upgraded in vitro approach for predicting in vivo genotoxicity of chemicals holding a great promise for reducing animal experimentations on genotoxicity.
Introduction
Although cancer is the second cause of death in USA and EU (1, 2) , this disease remains very complicated and not yet fully understood. However, two main causal factors for its development are appreciated: the presence of specific gene mutations genetically inherited or endogenously induced (3) and the exposure to exogenous carcinogenic factors (4) . Although hereditary cancers account for 5-10% of all diagnosed cancers, the remaining 90-95% of cancer incidence is due to environmental exposures, including exposures to chemical carcinogens (5, 6) . The molecular mechanism of chemical carcinogenesis frequently comprises the induction of DNA mutations by the carcinogen or its metabolites (7) but may also be promoted through a variety of mechanisms that do not involve DNA damage (8) . Consequently, carcinogens are classified as genotoxic (GTX) or nongenotoxic (NGTX) (7) . Since many GTX compounds also cause tumors in animal carcinogenic bioassays, it is important, in particular for regulatory purposes, to evaluate the genotoxic potential of chemicals to which humans are exposed, and thereby to discriminate GTX from NGTX compounds.
The most commonly used assays for detecting GTX compounds in vitro are the bacterial gene mutation assay (Ames test) (9) , the mammalian micronuclei (MN), the chromosomal aberration (CA), and the mouse lymphoma assays (MLA). For chemicals that are genotoxic in vitro, regulatory authorities may require the in vivo evaluation of genotoxic properties in rodents (EC 1907 (EC /2006 (10) . However, often the conventional in vitro test battery does not correspond with in vivo findings and thus fails to correctly predict the in vivo genotoxic and carcinogenic potential of compounds (10, 11) . Consequently, the high false positive rate (50% in some cases) (11) of in vitro genotoxicity assays results in a relatively high number of unnecessary animal experiments, which inflict considerable costs and raise ethical issues. Thus, a more reliable in vitro assay for predicting in vivo genotoxicity is urgently required. The socioeconomic necessity to reduce animal experiments (12) inspired the search for alternative in vitro methods thereby exploring novel technological approaches, such as toxicogenomics (13) . Toxicogenomics-based approaches have been explored for the development of genotoxicity classification tools showing that they are indeed capable of discriminating GTX from NGTX compounds (14) (15) (16) (17) .
Therefore, the aim of this study was to improve prediction of in vivo genotoxicity using an in vitro transcriptomics-based method. The human hepatic cell line HepG2 was selected for this purpose, as it expresses many drug metabolizing enzymes after chemical exposures (18) (19) (20) (21) (22) ; lacks mutations in p53 (23) and has been successfully applied in the phenotypic detection of genotoxic effects of chemicals that require metabolic activation (24) (25) (26) , in predictive transcriptomics studies (27) , in high through-put screening tools for genotoxicity (28) , and in the development of cost-effective approaches for efficiently prioritizing toxicity testing of chemicals by the EPA ToxCast™ project (29) .
In this study, transcriptomics alterations following HepG2 treatments for 12, 24 , and 48 h with 12 GTX and 22 NGTX chemicals were compared to select gene signatures that can be used for the prediction of in vivo genotoxicity. Further, we investigated whether a priori stratification of the compounds based on results of various in vitro genotoxicity tests improves the transcriptomics-based prediction. Validation was thereupon conducted using an additional set of 11 GTX and 17 NGTX chemicals. For the biological interpretation of the acquired gene signatures, functional annotation and transcriptional regulation network analyses of the selected classifiers were performed. Table I provides information on the selected doses and the stratification of the 34 compounds used for the development of the prediction model (A) and the 28 chemicals used for the validation (B) based on the Ames mutagenicity assay, on in vitro genotoxicity, and on in vivo genotoxicity results (positive or negative). More detailed information on the results of the conventional genotoxicity assays can be found in Supplementary Data 1, available at Carcinogenesis Online. A chemical is considered in vitro genotoxic when at least one in vitro genotoxicity assay (MN, CA, MLA) showed clear positive results since these three assays are currently considered equally appropriate and therefore interchangeable (30); a chemical is defined genotoxic in vivo when at least one in vivo genotoxicity assay (MN, CA) showed positive results since negative results in both the described in vivo assays are sufficient to demonstrate absence of genotoxicity (30) .
Materials and methods

Chemicals
Cell culture and treatment
HepG2 cells were cultured in six-well plates as previously described (27) . When the cells were 80% confluent, medium was replaced with fresh medium containing the corresponding dose of each compound or with the corresponding control treatment (DMSO, EtOH, or PBS 0.5%) ( Table I) .
All doses were selected based on a MTT assay resulting to 80% viability at 72 h incubation or a maximum dose of 2 mM when no cytotoxicity was observed (27) since according to the Fifth International Workshop on Genotoxicity Testing, it was agreed that the upper limit of 10 mM for in vitro cytogenetics assays could be reduced without losing sensitivity (31) . Cells were exposed for 12, 24, or 48 h for the training set of chemicals and for 24 and 48 h for the validation set. Thereafter, the culture medium was replaced by TRIZOL (Gibco/BRL) for RNA isolation. Three independent biological replicates were conducted.
Total RNA isolation and microarray experiments
Total RNA was extracted using 0.5 ml TRIZOL according to the manufacturer's instructions and purified using RNeasy ® Mini Kits (Qiagen). Sample preparation, hybridization, washing, staining, and scanning of the Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays were conducted according to the manufacturer's manual as previously described (27) . Quality controls were within acceptable limits. Hybridization controls were called present on all arrays and yielded the expected increases in intensities. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (32) and are accessible through GEO Series accession number GSE28878 (http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28878).
Annotation and normalization of microarray data. The obtained data sets were re-annotated to the MBNI Custom CDF-files (http://brainarray.mbni. med.umich.edu/Brainarray/Database/CustomCDF/genomic_curated_CDF. asp) (33) and RMA normalized (34) using the NuGOExpressionFileCreator in GenePattern (35) . Log2 ratios were calculated for each replicate to the corresponding control treatment. For the training set of chemicals, data filtering was conducted for each time point separately as described (27) . Only the filtered data sets were further used.
Selection of classifiers for genotoxicity
A schematic presentation of the method is provided as Supplementary  Figure 1 , available at Carcinogenesis Online.
Method 1: Genes with significantly different expression values (P < 0.01) between in vivo GTX and in vivo NGTX chemicals were selected from the filtered data sets based on a series of 34 t-tests. For each t-test, the three replicates of one of the 34 chemicals were removed (leave-one-out procedure). The significant genes that were present in the intersection of all lists resulting from the 34 t-tests were selected as classifiers.
Method 2: The 34 chemicals were stratified into two groups based on the results of the Ames mutagenicity assay and consequently assigned to Amespositive and Ames-negative. Within each group, both in vivo GTX and in vivo NGTX chemicals are present. For the Ames-positive and the Ames-negative group, 13 and 21 t-tests, respectively, were performed to select classifiers for discriminating in vivo GTX compounds from in vivo NGTX compounds, as mentioned for Method 1.
Method 3: The 34 chemicals were stratified into two groups based on the results of the in vitro genotoxicity assays into in vitro GTX and in vitro NGTX compounds. For the in vitro GTX group, 24 t-tests were performed to select classifiers that can discriminate in vivo GTX from in vivo NGTX compounds, as mentioned for Method 1. For the in vitro NGTX group, no t-tests were performed due to the presence of only one in vivo GTX compound.
Class prediction PAM (Prediction Analysis for Microarrays 2.13, Stanford University Software) analysis (36) was conducted for each of the selected lists of classifiers for class prediction (threshold: 0). For the prediction of the training set, the gene expression data (log2 ratios) of the three replicates of all compounds except one were used as training set (leave-one-out approach) to generate a predictive model, where after that model was tested with the left out compound. The leave-oneout approach was conducted for all the compounds in the training set. For the prediction of the validation set, a predictive model was developed using as training set the gene expression values of the selected classifiers after treatment with the training set of 34 chemicals (threshold: 0). The prediction models generated by the PAM software use only the gene expression of the classifier genes from the training set, to predict the properties of the compounds in the validation set. A compound was predicted to belong in the class (in vivo GTX or in vivo NGTX) to which at least two out of the three replicates were assigned.
The performance of the best prediction model was also evaluated by receiver-operator curve (ROC) analyses using the web-based calculator from Johns Hopkins University (http://www.rad.jhmi.edu/jeng/javarad/roc/ JROCFITi.html) (Figure 1 ). ROC analysis is a fundamental tool for diagnostic test evaluation and creates a complete sensitivity/specificity report.
Selection of differentially expressed genes
Differentially expressed genes (DEGs) per compound were selected using the criteria: absolute average fold change >1.5 in comparison to control, absolute fold change >1.2 for at least two replicates, and same direction of expression for all three replicates, as described (27) .
Functional annotation and transcription regulation analyses
Functional annotation based on Gene Ontology (GO) Biological Processes was done using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (37) . For each gene list, a background list resulting from the data filtering was used. GO terms were considered significant when Expression Analysis Systematic Explorer (EASE) < 0.1 and P-value <0.05 and included more than four genes. Identification of the transcription factors regulating the expression of the selected classifiers was conducted in MetaCore Network Tools (GeneGo, San Diego, CA) using the transcription regulation network option. Transcription regulation networks were taken into account when at least three of the classifiers were included in the network.
Results
Genotoxicity prediction
Three methods were applied for the selection of gene signatures for prediction of in vivo genotoxicity (Supplementary Figure 1 is available at Carcinogenesis Online). Based on the training set of compounds, first the classifier genes were selected. The gene expression values of these classifiers for the training set of compounds were used to build a prediction model in PAM, which was thereafter used to predict the in vivo GTX properties of the chemicals. Thus, only the expression values of the classifier genes obtained from the training set were used as a reference to which the expression values of the same genes in the validation set were compared in order to predict their properties. The accuracy, sensitivity, and specificity of all methods are presented in Table II . The selected classifiers from all methods and the predicted classes for each of the chemicals after the application of each method, for both the training and the validation set, are available in Supplementary Data 2, available at Carcinogenesis Online.
Class prediction based solely on transcriptomics data (Method 1) resulted in approximately 80% accuracy for all exposure durations, 
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with the highest sensitivity (67%) achieved at 48 h, and the highest specificity (95%) at 24 h (Table IIA) . In Method 2, two sets of classifiers were selected upon stratification of the chemicals based on the results of the Ames test: one set for Ames-positive and one for Ames-negative chemicals. These gene signatures resulted in high accuracy and sensitivity (92%) at 24 h of exposure.
In Method 3, chemicals were stratified based on the integrated outcome of the established in vitro genotoxicity test battery prior to the selection of classifiers. Since hardly any chemicals exist, which are Transcriptomics data after stratification of chemicals to GTX in vitro and NGTX in vitro. NGTX in vitro but GTX in vivo (only one compound in our study), this analysis was restricted only to compounds that are positive in in vitro genotoxicity testing. The selected gene signature for GTX in vitro chemicals resulted in approximately 80% accuracy for all exposure durations, in high sensitivity at 24 and 48 h of treatment (82%) and in the highest specificity at 24 h (85%). Since exposure periods of 24 and 48 h generate the most accurate prediction models, HepG2 cells were exposed for these periods to an additional set of 28 chemicals for the validation of the developed methods. This validation clearly shows that the highest accuracy, lowest positive and negative error rates, and highest positive and negative predictive values are achieved after 24 h of exposure using the gene-sets generated by Method 2 (Table IIB) . A comparison of the results obtained by this method to the outcomes of the conventional in vitro assays for the chemicals used in this study is presented in Table III . The performance of the most optimal prediction model was also evaluated by ROC analysis (Figure 1 ). This also demonstrates the good performance of our model because the area under the curves was always above 0.9.
The application of Method 2 after 24 h of exposure resulted in the misclassification of seven chemicals: APAP and AZA (GTX) and Sim, RR, PhB, 2-Cl, and Anis (NGTX). To elucidate causes of these misclassifications, DEGs after treatment with these compounds were selected and used for functional annotation analysis (Supplementary Data 3 is available at Carcinogenesis Online). Simtreatments resulted in the altered expression of, among others, four genes involved in DNA repair process. After RR-treatments, several of the DEGs appeared involved in metabolic processes, transcription, cell death/apoptosis, and cell cycle-related processes. DEGs resulting after 2Cl and Anis were mainly involved in metabolic processes, whereas DEGs after PhB treatments were not significantly involved in any biological process.
APAP-treatment resulted in only one gene differentially expressed (RRN3P2), thus no functional annotation analysis was possible. Conversely, AZA altered the expression of more than 2500 genes, from which 28 are involved in double-strand break repair, 23 in nucleotide excision repair, and 11 in base excision repair.
Finally, we evaluated the most optimal prediction method with another, completely independent, set of transcriptomics data for 21 compounds, of which 15 were not tested before. These transcriptomics data were obtained either from (i) in-house studies at Janssen Pharmaceutica, Beerse, Belgium, using their HepG2 line with 24 h treatment time at near toxic doses, (ii) unpublished studies at Maastricht University from other projects on HepG2 cells, and (iii) new additional studies using compounds that were selected for the EU-FP carcinoG-ENOMICS project (38) but that were not yet present in our training and validation sets. Again, a good prediction was obtained, with only two compounds (rifampicin and tetracycline) being falsely misclassified as NGTX (Supplementary Data 4, available at Carcinogenesis Online). The five compounds that were also present in the training/ validation set were all correctly classified.
Functional annotation and transcriptional regulation network analyses of classifiers
The classifiers selected after 24 h of treatment by Method 2 are shown in Table IV . The functional annotation analysis for the 33 classifiers for Ames-positive compounds did not reveal any GO terms. However, five transcription factors were identified, which appear to regulate the expression of some of these classifiers. In particular, HNF4a appears to regulate the expression of TTR, CEACAM1, NAT8, SNX11, and C10orf10; SP1 the expression of ROBO4, GMFG, SLC27A1, and TPK1; HNF3a the expression of TTR and TPK1; androgen receptor (AR) the expression of BCOR and RBPMS; and lastly, HNF6 the expression of TTR, CLCN4, and NR0B2. These transcription networks are involved in response to stimulus (HNF4a), metabolic and developmental processes (SP1, HNF3a, AR, and HNF6), and signaling (AR). NR0B2 (SHP), one of the classifiers, appears to negatively regulate the function of four of these transcription factors (HNF4a, HNF3a, AR, and HNF6). A network showing the direct interactions among these transcription factors and the identified classifiers is presented in Figure 2 .
Out of the 22 classifiers for Ames-negative compounds, eight (AGFG1, NDUFA10, ANXA6, APOA4, LGTN, SGK1, SLC40A1, SLC6A4) are involved in GO-terms for transport and localization and six (APOA4, FGA, MTMR15, NFATC3, PLAA, SGK1) in response to stress. Most of these genes showed higher expression levels for GTX than for NGTX compounds. Within this set of 22 genes, no significant transcriptional regulation networks were identified.
Discussion
In this study, we aimed at developing an alternative in vitro transcriptomics-based method in HepG2 cells for predicting in vivo genotoxicity of chemicals. The best accuracy was achieved using gene-sets selected after stratification of chemicals based on results of the Ames assay (Method 2) and after 24 h of exposure. This exposure duration leads to the most accurate predictions probably due to the required time of some chemicals to be metabolized and thus genotoxic effects may not be detected in earlier time points, whereas later exposures may have already led to the repair of genotoxic effects observed at 24 h of exposure. The high accuracy of this method in comparison to the other methods developed here is probably due to the fact that the Ames assay has the highest specificity among the traditional in vitro genotoxicity assays (11) .
Additionally, the developed method results in an improved accuracy and specificity and thus in a clear reduction of the false-positive results (13%) in comparison to the conventional in vitro assays (Table  III) . With our method, only five NGTX compounds, namely Sim, PhB, 2Cl, Anis, and RR, were misclassified as GTX. Functional annotation analysis revealed genes associated with DNA-damage responses only after Sim-treatment, suggesting that DNA-damage may have been induced. Sim has given negative results in in vivo MN studies (39, 40) , whereas in a SCGE assay, Sim showed weak signs of genotoxicity Accuracy  77%  89%  60%  60%  91%  63%  62%  88%  68%  89%  Sensitivity  78%  91%  94%  94%  100%  96%  96%  91%  96%  91%  False negative rate  22%  9%  6%  6%  0%  4%  4%  9%  4%  9%  Specificity  77%  87%  42%  42%  97%  46%  40%  86%  51%  87%  False positive rate  23%  13%  58%  58%  3%  54%  60%  14%  49%  13% GE, gene expression. Transcriptomics-based in vitro assay (41) . Since these studies were performed for bone marrow or blood cells, it cannot be excluded that Sim may have genotoxic effects to other cell types, e.g. liver, and this effect may be represented in our assay. PhB also appeared NGTX in the in vivo MN assay, but positive results were obtained for the SCGE assay (42) , showing that the genotoxic effects of PhB in vivo are not fully elucidated yet. PhB is known to induce CAR transcriptional activity leading to overexpression of CYP2B (43, 44) . In our study, PhB did not induce the overexpression of CYP2B enzymes in HepG2, suggesting that PhB did not cause the activation of CAR. This may have led to the activation of other mechanisms that resulted to its classification as GTX. Similarly, the available in vivo studies for 2Cl show contradicting genotoxic effects: with negative results in mice but positive in rats (45) . Anis was only tested in the MN assay resulting in a negative outcome (Table I , Supplementary Data 1, available at Carcinogenesis Online), indicating that the available data for both 2Cl and Anis may not have been sufficient for their assignment as nongenotoxic, possible explaining their prediction by our method as GTX. RR-treatments resulted in the altered expression levels of more than 2000 genes. We hypothesize that this massive transcriptomics response is due to the applied high dose (2 mM). Despite that, this dose did not induce cytotoxicity; it resulted in a massive deregulation of the expression of genes associated to apoptosis/ cell death and, thus, indirectly to its classification as GTX. Furthermore, our method results in a lower false-negative rate (9%) than the Ames test (22%) and in similar false-negative rate as the other classical in vitro assays (Table III) . By our assay only two genotoxic chemicals, namely AZA and APAP, were classified as NGTX. Although the IARC monographs for both AZA and APAP present positive data for in vivo genotoxicity in rodents (39, 46) , their ability to induce genotoxic effects in humans is doubtful (47, 48) . Thus, the prediction of these chemicals as NGTX by our method may better represent their effects to humans. Although, AZA altered the expression of genes involved in DNA-repair processes, its genotoxic activity was not detected by the selected classifiers. With respect to APAP, it has been reported that this compound induces genotoxicity in vitro and in vivo only at high, nonphysiological doses (48, 49) . In addition, APAP-induced genotoxicity in vivo has been attributed to the induced cytotoxicity at high doses (49) . In our study, treatment with 100 µM APAP, corresponding to 20% cytotoxicity, resulted in only one gene differentially expressed and its classification as NGTX. These observations suggest that the selected dose was not sufficient for APAP to exert its cytotoxic and genotoxic effect corresponding with studies linking its genotoxicity to high cytotoxicity.
A second, independent, set of validation compounds were evaluated, which again demonstrated the accurateness of the prediction model (Supplementary Data 4, available at Carcinogenesis Online). The two compounds that gave false-negative results, rifampicin and tetracycline, both are antibiotics, and more importantly, also both are NGTX according to the classical in vitro genotoxicity tests. Thus apparently the in vivo genotoxic properties of these compounds cannot be observed in vitro. Noteworthy, tetracycline is an IARC class 3 compound; thus, the carcinogenic risk is not known and the in vivo GTX test may in fact be a false-positive result. According to the NTP database, rifampicin is carcinogenic, though only in female mice.
For the biological understanding of the selected classifiers, functional annotation and transcriptional regulation analyses were performed. Five transcription factors were identified to regulate the expression of the classifiers for Ames-positive compounds: AR, a ligand-dependent transcription factor that has been linked to the development of prostate cancer (50) ; SP1 that has been linked with DNA damage responses (51); and HNF3a, HNF4a, and HNF6 that regulate the expression of liver-specific genes (52) . Particularly, Information on the function of the classifiers was retrieved from MetaCore.
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HNF4a is responsible for the regulation of expression of genes involved, among others, in drug and xenobiotic metabolism (53) . Furthermore, NR0B2, one of the selected classifiers, was identified to negatively regulate the function of HNF3a, HNF4a, HNF6a, and AR ( Figure 2 ). NR0B2 is a known inhibitor of transcription and has been proposed as a tumor suppressor gene for hepatocellular carcinoma (54) . The increased expression levels of NR0B2 after treatments with genotoxic, Ames-positive chemicals in this study suggest a possible role of this gene in the development of chemically induced genotoxicity by compounds that cause mutagenicity to both bacterial and mammalian cells. Although the selected genes are not directly linked to known pathways of genotoxicity, the above-mentioned functionalities subscribe to the biological plausibility of the identified gene signature for predicting genotoxicity in vivo, and future studies on their biological role is required to further establish their involvement in genotoxic responses. For the classifiers that predict genotoxicity in vivo for Amesnegative compounds, over-representation analyses indicated enrichment of classifiers in cellular stress responses. SGK1 was identified by PAM as the gene with the highest contribution to the prediction model. This gene plays an important role in stress response and cell survival and has been proposed as an oncogene related to breast cancer development (55, 56) . The high expression values of SGK1 after treatments with genotoxic, Ames-negative chemicals suggest a possible involvement of this gene in genotoxicity induction by compounds that cause mutagenicity to mammalian but not to bacterial cells.
The developed approach for in vivo genotoxicity prediction may facilitate the reduction of animal experimentations. For instance, it may serve the purposes of the EU chemical policy program REACH, for which it has been estimated that approximately 400 000 rodents may be used for testing genotoxicity in vivo (57), many of which will be based on false premises from in vitro studies. Further, it may improve hazard identification of existing industrial chemicals and may be effective in drug development, by significantly avoiding false-positive results of the standard in vitro genotoxicity test battery, implying that promising lead compounds will no longer be eliminated due to wrong assumptions on their genotoxic properties and that rodents would not be unnecessarily killed in costly follow-up experiments. Finally, this method may also be applied for assessing genotoxic properties of novel cosmetics since in the EU animal testing is prohibited for cosmetic ingredients (EC Regulation 1223/2009). Due to the small number of genes required for this assay-33 for Ames-positive compounds and 22 for Ames-negative compounds-several technological options may be considered for high-throughput applications.
Our stratification approach, unfortunately, had one major drawback, namely an uneven distribution of chemical compounds in the various categories. This is particularly the case for the two validation sets, resulting in low number of Ames-positive compounds that are NGTX in vivo (only two) and the Ames-negative compounds that are GTX in vivo (one). The chemical selection and division in training and validation sets were based on roughly equal numbers of in vivo GTX, in vivo NGTX, and in vitro false-positive GTX compounds, without considering further subclasses. Almost equal numbers of Ames-positive or Ames-negative compounds were also included. However, it was not a goal to have these equally distributed over all the various other subclasses because at the start of the study, we could not yet know which stratification method would be preferred. Furthermore, the low number of "Ames-positive compounds that are NGTX in vivo" is not The circles next to the symbols indicate the expression of the genes for GTX and NGTX compounds (average log2 ratios). Red circles indicate up-regulation and blue circles down-regulation after both GTX and NGTX treatments; the "checkerboard" color indicates mixed expression between GTX and NGTX compounds.
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a major problem because only a few of these compounds are known. In a recent review from Kirkland et al. on 460 compounds, 11 would fall into this class, many of them (6) are however weak (equivocal) in vivo GTX (58) . The remaining five were not included by us, as unfortunately, this review was published a long time after we selected the compounds. In the same review, also more "Ames-negative compounds that are genotoxic in vivo" are mentioned, which were not selected by us. In future follow-up studies, these compounds would be good candidates to further evaluate our assay.
Conclusion
In conclusion, this study demonstrates that the evaluation of specific gene expression alterations in HepG2 cells after 24 h of treatment with chemicals under investigation, in combination with results from the Ames test, can successfully predict their genotoxic hazard in vivo. This prediction model in combination with analysis of compoundspecific transcriptomics responses provides additional relevant mechanistic information. This method has a greatly improved specificity compared with other in vitro tests, while maintaining a similar high sensitivity. Eventually, this method may contribute to the reduction of animal experimentations complying with 3R strategies. However, upon negative results of this assay, rodent carcinogenic bioassays may still need to be considered due to the variety of nongenotoxic modesof-actions that cannot be identified by this method.
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